Semler Scientific Inc (SMLR)

$42.55

+0.64

(+1.53%)

Market is closed - opens 8 PM, 07 Dec 2023

Insights on Semler Scientific Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 18.60M → 16.31M (in $), with an average decrease of 12.3% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 5.87M → 5.51M (in $), with an average decrease of 6.2% per quarter

Performance

  • $41.86
    $42.99
    $42.55
    downward going graph

    1.62%

    Downside

    Day's Volatility :2.63%

    Upside

    1.02%

    downward going graph
  • $19.12
    $43.39
    $42.55
    downward going graph

    55.06%

    Downside

    52 Weeks Volatility :55.93%

    Upside

    1.94%

    downward going graph

Returns

PeriodSemler Scientific IncSector (Health Care)Index (Russel 2000)
3 Months
63.21%
0.0%
0.0%
6 Months
55.92%
2.2%
0.0%
1 Year
39.28%
-4.7%
-2.1%
3 Years
-66.5%
18.0%
-6.5%

Highlights

Market Capitalization
280.0M
Book Value
$10.52
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
2.5
PE Ratio
16.29
PEG Ratio
0.0
Wall Street Target Price
65.0
Profit Margin
29.26%
Operating Margin TTM
42.28%
Return On Assets TTM
21.33%
Return On Equity TTM
31.8%
Revenue TTM
66.9M
Revenue Per Share TTM
9.98
Quarterly Revenue Growth YOY
16.2%
Gross Profit TTM
52.4M
EBITDA
24.2M
Diluted Eps TTM
2.5
Quarterly Earnings Growth YOY
0.54
EPS Estimate Current Year
2.65
EPS Estimate Next Year
3.37
EPS Estimate Current Quarter
0.51
EPS Estimate Next Quarter
0.47

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Semler Scientific Inc(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 52.76%

Current $42.55
Target $65.00

Company Financials

FY17Y/Y Change
Revenue
12.5M
↑ 67.5%
Net Income
-1.5M
↓ 40.88%
Net Profit Margin
-12.13%
↑ 22.23%
FY18Y/Y Change
Revenue
21.5M
↑ 72.59%
Net Income
5.0M
↓ 432.05%
Net Profit Margin
23.33%
↑ 35.46%
FY19Y/Y Change
Revenue
32.8M
↑ 52.47%
Net Income
15.1M
↑ 200.84%
Net Profit Margin
46.03%
↑ 22.7%
FY20Y/Y Change
Revenue
38.6M
↑ 17.81%
Net Income
14.0M
↓ 7.14%
Net Profit Margin
36.28%
↓ 9.75%
FY21Y/Y Change
Revenue
53.0M
↑ 37.36%
Net Income
17.2M
↑ 22.95%
Net Profit Margin
32.48%
↓ 3.8%
FY22Y/Y Change
Revenue
56.7M
↑ 6.9%
Net Income
14.3M
↓ 16.82%
Net Profit Margin
25.27%
↓ 7.21%
Q2 FY22Q/Q Change
Revenue
14.8M
↑ 5.79%
Net Income
4.1M
↑ 21.25%
Net Profit Margin
27.48%
↑ 3.51%
Q3 FY22Q/Q Change
Revenue
14.0M
↓ 5.27%
Net Income
3.7M
↓ 9.79%
Net Profit Margin
26.16%
↓ 1.32%
Q4 FY22Q/Q Change
Revenue
13.8M
↓ 1.8%
Net Income
3.2M
↓ 12.49%
Net Profit Margin
23.31%
↓ 2.85%
Q1 FY23Q/Q Change
Revenue
18.2M
↑ 31.98%
Net Income
5.0M
↑ 54.51%
Net Profit Margin
27.29%
↑ 3.98%
Q2 FY23Q/Q Change
Revenue
18.6M
↑ 2.19%
Net Income
5.9M
↑ 18.31%
Net Profit Margin
31.6%
↑ 4.31%
Q3 FY23Q/Q Change
Revenue
16.3M
↓ 12.3%
Net Income
5.5M
↓ 6.21%
Net Profit Margin
33.8%
↑ 2.2%
FY17Y/Y Change
Total Assets
4.2M
↑ 37.96%
Total Liabilities
6.8M
↑ 13.85%
FY18Y/Y Change
Total Assets
7.7M
↑ 82.14%
Total Liabilities
3.5M
↓ 48.35%
FY19Y/Y Change
Total Assets
18.3M
↑ 136.91%
Total Liabilities
5.2M
↑ 48.0%
FY20Y/Y Change
Total Assets
34.6M
↑ 89.42%
Total Liabilities
4.8M
↓ 7.06%
FY21Y/Y Change
Total Assets
50.7M
↑ 46.29%
Total Liabilities
5.1M
↑ 5.76%
FY22Y/Y Change
Total Assets
62.7M
↑ 23.72%
Total Liabilities
7.0M
↑ 36.92%
Q2 FY22Q/Q Change
Total Assets
57.6M
↑ 3.97%
Total Liabilities
7.0M
↑ 15.27%
Q3 FY22Q/Q Change
Total Assets
60.9M
↑ 5.7%
Total Liabilities
8.6M
↑ 22.98%
Q4 FY22Q/Q Change
Total Assets
62.7M
↑ 2.91%
Total Liabilities
7.0M
↓ 18.09%
Q1 FY23Q/Q Change
Total Assets
70.3M
↑ 12.07%
Total Liabilities
9.1M
↑ 29.06%
Q2 FY23Q/Q Change
Total Assets
75.5M
↑ 7.41%
Total Liabilities
10.2M
↑ 12.62%
Q3 FY23Q/Q Change
Total Assets
79.4M
↑ 5.28%
Total Liabilities
8.7M
↓ 14.99%
FY17Y/Y Change
Operating Cash Flow
621.0K
↓ 134.42%
Investing Cash Flow
-968.0K
↑ 18.92%
Financing Cash Flow
1.2M
↓ 58.31%
FY18Y/Y Change
Operating Cash Flow
4.7M
↑ 656.36%
Investing Cash Flow
-843.0K
↓ 12.91%
Financing Cash Flow
-2.0M
↓ 271.49%
FY19Y/Y Change
Operating Cash Flow
12.7M
↑ 170.98%
Investing Cash Flow
-1.7M
↑ 101.42%
Financing Cash Flow
-6.6M
↑ 224.27%
FY20Y/Y Change
Operating Cash Flow
15.4M
↑ 21.13%
Investing Cash Flow
-1.3M
↓ 22.91%
Financing Cash Flow
230.0K
↓ 103.5%
FY21Y/Y Change
Operating Cash Flow
16.1M
↑ 4.14%
Investing Cash Flow
-825.0K
↓ 36.97%
Financing Cash Flow
13.0K
↓ 94.35%
FY22Y/Y Change
Operating Cash Flow
17.5M
↑ 8.76%
Investing Cash Flow
-26.8M
↑ 3152.73%
Financing Cash Flow
-4.9M
↓ 38076.92%
Q2 FY22Q/Q Change
Operating Cash Flow
6.2M
↑ 314.78%
Investing Cash Flow
-1.8M
↑ 595.7%
Financing Cash Flow
-2.8M
↑ 1888.81%
Q3 FY22Q/Q Change
Operating Cash Flow
8.0M
↑ 28.75%
Investing Cash Flow
-491.0K
↓ 72.43%
Financing Cash Flow
-2.0M
↓ 28.8%
Q4 FY22Q/Q Change
Operating Cash Flow
1.7M
↓ 78.68%
Investing Cash Flow
-24.3M
↑ 4850.51%
Financing Cash Flow
75.0K
↓ 103.7%
Q1 FY23Q/Q Change
Operating Cash Flow
861.0K
↓ 49.65%
Investing Cash Flow
-18.4M
↓ 24.2%
Financing Cash Flow
-146.0K
↓ 294.67%
Q2 FY23Q/Q Change
Operating Cash Flow
11.2M
↑ 1200.35%
Investing Cash Flow
25.0M
↓ 235.52%
Financing Cash Flow
-2.0M
↑ 1252.74%

Technicals Summary

Sell

Neutral

Buy

Semler Scientific Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Semler Scientific Inc
Semler Scientific Inc
41.88%
55.92%
39.28%
-66.5%
-66.5%
Stryker Corporation
Stryker Corporation
4.68%
3.56%
18.92%
21.57%
70.49%
Dexcom, Inc.
Dexcom, Inc.
23.9%
-1.48%
0.03%
39.82%
288.57%
Boston Scientific Corp.
Boston Scientific Corp.
5.08%
8.13%
20.14%
60.06%
54.51%
Abbott Laboratories
Abbott Laboratories
10.7%
3.23%
0.12%
-2.09%
50.02%
Medtronic Plc
Medtronic Plc
9.05%
-4.64%
2.77%
-29.81%
-16.13%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Semler Scientific Inc
Semler Scientific Inc
16.29
16.29
0.0
2.65
0.32
0.21
0.0
10.52
Stryker Corporation
Stryker Corporation
44.25
44.25
2.89
10.41
0.15
0.07
0.01
47.13
Dexcom, Inc.
Dexcom, Inc.
128.52
128.52
2.39
1.43
0.18
0.06
0.0
5.87
Boston Scientific Corp.
Boston Scientific Corp.
68.46
68.46
1.75
2.01
0.07
0.04
0.02
12.89
Abbott Laboratories
Abbott Laboratories
35.67
35.67
25.14
4.44
0.14
0.06
0.02
21.59
Medtronic Plc
Medtronic Plc
25.97
25.97
1.61
5.28
0.08
0.04
0.03
38.69
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Semler Scientific Inc
Semler Scientific Inc
Buy
$280.0M
-66.5%
16.29
29.26%
Stryker Corporation
Stryker Corporation
Buy
$113.1B
70.49%
44.25
13.0%
Dexcom, Inc.
Dexcom, Inc.
Buy
$45.1B
288.57%
128.52
11.08%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$82.2B
54.51%
68.46
8.93%
Abbott Laboratories
Abbott Laboratories
Buy
$182.1B
50.02%
35.67
12.92%
Medtronic Plc
Medtronic Plc
Buy
$106.4B
-16.13%
25.97
12.84%

Institutional Holdings

  • HPM Partners LLC

    10.41%
  • Vanguard Group Inc

    4.87%
  • BlackRock Inc

    4.71%
  • LSV Asset Management

    2.15%
  • CI Private Wealth LLC

    1.85%
  • AltraVue Capital, LLC

    1.81%

Company Information

semler scientific, inc. is an emerging medical risk-assessment company whose diagnostic and testing products and services help to guide patient care and close the gap between cost of care and compensation for care. semler closed the initial public offering of its common stock on february 26, 2014 and its common stock is now listed under the ticker symbol "smlr."​ additional information about semler can be found at www.semlerscientific.com.

Organization
Semler Scientific Inc
Employees
127
CEO
Dr. Douglas Murphy-Chutorian M.D.
Industry
Medical Specialties

FAQs